Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

mAbs

Volumn 2, Issue 4, 2010, Pages 428-439

  Shealy, David ^a   Cai, Ann ^a   Staquet, Kim ^a   Baker, Audrey ^a   Lacy, Eilyn R ^a   Johns, Laura ^a   Vafa, Omid ^a   Gunn III, George ^a   Tam, Susan ^a   Sague, Sarah ^a   Wang, Dana ^a   Brigham Burke, Mike ^a   Dalmonte, Paul ^a   Emmell, Eva ^a   Pikounis, Bill ^a   Bugelski, Peter J ^a   Zhou, Honghui ^a   Scallon, Bernard ^a   Giles Komar, Jill ^a  

^a CENTOCOR INC   (United States)

Author keywords

Affinity; Arthritis; Bioassay; Golimumab; Neutralization; Solubility; Stability; TNF

Indexed keywords

ADALIMUMAB; CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BINDING AFFINITY; CARTILAGE INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HYBRIDOMA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELTING POINT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCORING SYSTEM; SURFACE PLASMON RESONANCE; TRANSGENIC MOUSE; ANIMAL; ANTIBODY AFFINITY; C57BL MOUSE; CARTILAGE; CBA MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PROTEIN CONFORMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ARTHRITIS; CARTILAGE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; E-SELECTIN; GENE EXPRESSION REGULATION; HYBRIDOMAS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; PROTEIN CONFORMATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958520182     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.12304     Document Type: Article

References (41)

1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
2. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFa blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126:121-36.
3. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004; 18:59-80. (Pubitemid 38324659)
4. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007; 11:1369-84. (Pubitemid 350200476)
5. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3:220-8.
6. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24:438-47. (Pubitemid 44332869)
7. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005; 34:12-8.
8. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-16.
9. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:353-63. (Pubitemid 38198818)
10. Immunex Corporation. Enbrel® (etanercept) package insert. Thousand Oaks, CA 2000.
11. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400-11. (Pubitemid 38608061)
12. Abbott Laboratories. Humira® (adalimumab) package insert. Abbott Park, IL 2009.
13. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-9.
14. Centocor. Remicade® (infliximab) package insert. Malvern, PA 2009.
15. Lefranc MP. IMGT-ONTOLOGY and IMGT databases, tools and Web resources for immunogenetics and immunoinformatics. Mol Immunol 2004; 40:647-60.
16. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgG1 monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnology 1996; 14:845-51.
17. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNFalpha antibody in rheumatoid arthritis. Mol Pathol 1997; 50:225-33.
18. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-31.
19. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 2008; 58:964-75.
20. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29:1-9. (Pubitemid 43756076)
21. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20:450-9.
22. Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol 2008; 181:101-29.
23. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45:124-31.
24. Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 2006; 36:2768-80. (Pubitemid 44608460)
25. Dijstelbloem HM, van de Winkel JG, Kallenberg CG. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 2001; 22:510-6.
26. Roopenian DS, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25. (Pubitemid 47327396)
27. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFa and activates immune effector functions. Cytokine 1995; 7:251-9.
28. Catrina AI, Trollmo C, Klint EA, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints. Arthritis Rheum 2005; 52:61-72. (Pubitemid 40129233)
29. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48:2155-62.
30. Ringheaunu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004; 10:801-10.
31. Wollin M, Abele S, Bruns S, Weyand M, Kalden JR, Ensminger SM, et al. Inhibition of TNFalpha reduces transplant arteriosclerosis in a murine aortic transplant model. Transplant Int 2009; 22:342-9.
32. Deveci F, Muz MH, Ilhan N, Kirkil G, Turgut T, Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology 2008; 13:488-97.
33. Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, et al. Anti-TNFα antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 2002; 4:7.
34. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNFalpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007; 47:383-96.
35. Zhou H, Xu Z, Rahman MU, Wagner C, Pendley C, Han J, et al. Exposure-efficacy assessment of golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: application of population pharmacokinetic/pharmacodynamic modeling. Arthritis Rheum 2006; 54:5418.
36. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007; 27:793-806.
37. Taylor LD, Carmack CE, Huszar D, Higgins KM, Mashayekh R, Sequar G, et al. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int Immunology 1993; 6:579-91.
38. Scallon BJ, Cai A, Solowski N, Rosenberg A, Song X-Y, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
39. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63:251-8.
40. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000; 80:1195-205.
41. Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diarecein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 2004; 6:65-72.